PBAC Public Summary Documents – March 2025
Page last updated: 4 July 2025
Public Summary Documents relating to the March 2025 PBAC meeting.
- Dabrafenib and Trametinib; Capsule 50 mg (as mesilate), Capsule 75 mg (as mesilate); Tafinlar®; Trametinib, Tablet 500 micrograms, Tablet 2 mg; Mekinist®
- Dapsone; Tablet 50 mg; Dapsomed®
- Daratumumab; Solution for I.V. infusion 100 mg in 5 mL vial, Solution for I.V. infusion 400 mg in 20 mL vial, Solution for S.C. injection 1,800 mg in 15 mL vial; Darzalex®
- Denosumab; Injection 120 mg in 1 mL single use pre-filled syringe; Xgeva®
- Dupilumab; Injection 200 mg in 1.14 mL single dose pre-filled pen, Injection 300 mg in 2 mL single dose prefilled pen; Dupixent®
- Eflornithine; Tablet 192 mg (as hydrochloride); Ifinwil®
- Elafibranor; Tablet 80 mg; Iqirvo®
- Elexacaftor with Tezacaftor and with Ivacaftor, and Ivacaftor; Pack containing 56 tablets Elexacaftor 100 mg with Tezacaftor 50 mg and with Ivacaftor 75 mg and 28 tablets Ivacaftor 150 mg, Pack containing 56 tablets Elexacaftor 50 mg with Tezacaftor 25 mg and with ivacaftor 37.5 mg and 28 tablets Ivacaftor 75 mg, Pack containing 28 sachets Elexacaftor 100 mg with Tezacaftor 50 mg and with Ivacaftor 75 mg and 28 sachets Ivacaftor 75 mg, Pack containing 28 sachets Elexacaftor 80 mg with Tezacaftor 40 mg and with Ivacaftor 60 mg and 28 sachets Ivacaftor 59.5 mg; Trikafta®
- Elranatamab; Solution for subcutaneous injection 44 mg in 1.1 mL (40 mg per mL), Solution for subcutaneous injection 76 mg in 1.9 mL (40 mg per mL); Elrexfio®
- Estetrol with Drospirenone; Pack containing 24 tablets estetrol 14.2 mg with drospirenone 3 mg and 4 inert tablets; Nextstellis®
- Faricimab; Solution for intravitreal injection 21 mg in 0.175 mL (120 mg per mL) pre-filled syringe; Vabysmo®
- Gemcitabine; Solution for injection 1 g (as hydrochloride) in 25 mL, Solution for injection 2 g (as hydrochloride) in 50 mL; Gemcitabine Sandoz®
- Infliximab; Solution for injection 120 mg in 1 mL pre-filled pen, Solution for injection 120 mg in 1 mL pre-filled syringe; Remsima® SC
- Infliximab; Powder for I.V. infusion 100 mg; Ixifi®
- Ivacaftor; Sachet containing granules 13.4 mg; Kalydeco®
- Lumasiran; Solution for subcutaneous injection 94.5 mg in 0.5 mL; Oxlumo®
- Midostaurin; Capsule 25 mg; Rydapt®
- Natalizumab; Solution concentrate for I.V. infusion 300 mg in 15 mL; Tyruko®
- Omalizumab; Injection 75 mg in 0.5 mL single dose pre-filled syringe, Injection 150 mg in 1 mL single dose pre-filled syringe; Omlyclo®
- Omalizumab; Injection 75 mg in 0.5 mL single dose pre-filled syringe, Injection 150 mg in 1 mL single dose pre-filled syringe, Injection 300 mg in 2 mL single dose pre-filled syringe, Injection 75 mg in 0.5 mL single dose pre-filled pen, Injection 150 mg in 1 mL single dose pre-filled pen, Injection 300 mg in 2 mL single dose pre-filled pen; Xolair®
- Pembrolizumab; Solution concentrate for I.V. infusion 100 mg in 4 mL; Keytruda®
- Ruxolitinib; Tablet 5 mg, Tablet 10 mg, Tablet 15 mg, Tablet 20 mg; Jakavi®
- Toripalimab; Solution concentrate for I.V. infusion 240 mg in 6 mL (40 mg per mL); Zytorvi®
- Ustekinumab; Injection 45 mg in 0.5 mL single use pre-filled syringe, Injection 90 mg in 1 mL single use pre-filled syringe, Solution concentrate for I.V. infusion 130 mg in 26 mL (5 mg per mL); Epyztek®
The following Public Summary Documents have been updated:
